Literature DB >> 17000074

To know or not to know: a review of behaviour and suicidal ideation in preclinical Huntington's disease.

Tarja-Brita Robins Wahlin1.   

Abstract

OBJECTIVE: At present, the problems associated with suicidal ideation and suicide in Huntington's disease (HD), worldwide, are much the same as 2 decades ago. This study seeks to investigate the psychological complications of predictive testing in HD at risk populations.
METHODS: The key problems of predictive testing, fear of acquiring carrier status, psychological consequences, autonomy, and rights to know are discussed.
RESULTS: This review (1) describes psychological affect and problems of persons facing the decision to test for HD, (2) discusses suicidal ideation, behaviour, and catastrophic events associated with predictive testing, (3) assesses ethical questions raised in the genetic counselling, (4) questions whether counsellors should promote or advocate predictive testing, and finally (5) discusses what professionalism actually is in genetic counselling.
CONCLUSION: The need for professional counselling, using a well designed protocol, and the importance of focusing on the suicide risk of participants in predictive testing programs are emphasized. PRACTICE IMPLICATIONS: The counsellor has an obligation to provide adequate information. The professionals should not promote nor advocate presymptomatic DNA-testing. Depression, hopelessness, anxiety, emotional distress, suicidal tendencies, and social dysfunction grading should be considered in predictive testing of HD.

Entities:  

Mesh:

Year:  2006        PMID: 17000074     DOI: 10.1016/j.pec.2006.08.009

Source DB:  PubMed          Journal:  Patient Educ Couns        ISSN: 0738-3991


  27 in total

1.  The right to ignore genetic status of late onset genetic disease in the genomic era; Prenatal testing for Huntington disease as a paradigm.

Authors:  A Erez; K Plunkett; V R Sutton; A L McGuire
Journal:  Am J Med Genet A       Date:  2010-07       Impact factor: 2.802

2.  Validation of Neuro-QoL and PROMIS Mental Health Patient Reported Outcome Measures in Persons with Huntington Disease.

Authors:  Noelle E Carlozzi; Siera Goodnight; Anna L Kratz; Julie C Stout; Michael K McCormack; Jane S Paulsen; Nicholas R Boileau; David Cella; Rebecca E Ready
Journal:  J Huntingtons Dis       Date:  2019

3.  Direct-to-Consumer Genomics: Harmful or Empowering?: It is important to stress that genetic risk is not the same as genetic destiny.

Authors:  Joel C Eissenberg
Journal:  Mo Med       Date:  2017 Jan-Feb

4.  Reconceptualizing harms and benefits in the genomic age.

Authors:  Anya E R Prince; Benjamin E Berkman
Journal:  Per Med       Date:  2018-09-27       Impact factor: 2.512

5.  Sequencing Newborns: A Call for Nuanced Use of Genomic Technologies.

Authors:  Josephine Johnston; John D Lantos; Aaron Goldenberg; Flavia Chen; Erik Parens; Barbara A Koenig
Journal:  Hastings Cent Rep       Date:  2018-07       Impact factor: 2.683

6.  Factors related to genetic testing in adults at risk for Huntington disease: the prospective Huntington at-risk observational study (PHAROS).

Authors:  K A Quaid; S W Eberly; E Kayson-Rubin; D Oakes; I Shoulson
Journal:  Clin Genet       Date:  2016-11-24       Impact factor: 4.438

Review 7.  Preimplantation genetic diagnosis for inherited neurological disorders.

Authors:  Ilan Tur-Kaspa; Roohi Jeelani; P Murali Doraiswamy
Journal:  Nat Rev Neurol       Date:  2014-05-27       Impact factor: 42.937

8.  Fear of health insurance loss among individuals at risk for Huntington disease.

Authors:  Emily Oster; E Ray Dorsey; Jan Bausch; Aileen Shinaman; Elise Kayson; David Oakes; Ira Shoulson; Kimberly Quaid
Journal:  Am J Med Genet A       Date:  2008-08-15       Impact factor: 2.802

9.  Balancing personalized medicine and personalized care.

Authors:  Kenneth Cornetta; Candy Gunther Brown
Journal:  Acad Med       Date:  2013-03       Impact factor: 6.893

10.  Public perceptions of presymptomatic testing for Alzheimer disease.

Authors:  Richard J Caselli; Jessica Langbaum; Gary E Marchant; Rachel A Lindor; Katherine S Hunt; Bruce R Henslin; Amylou C Dueck; Jason S Robert
Journal:  Mayo Clin Proc       Date:  2014-08-26       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.